Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Items 201–300 of 550
Nirschl, C. J., Brodkin, H. R., Domonkos, C., Dwyer, C. J., Hicklin, D. J., Ismail, N. S., Seidel‐Dugan, C., Steiner, P., Steuert, Z., Sullivan, J. M., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0705 · Cited by 24
Jiang, R., Yang, L., Liu, X., Xu, Y., Han, L., Chen, Y., Gao, G., Wang, M., Su, T., Li, H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.024 · Cited by 25
Polyphosphazenes for the delivery of biopharmaceuticals
Hsu, W., Csaba, N., Alexander, C., & García-Fuentes, M. (2019) · Journal of Applied Polymer Science · doi:10.1002/app.48688 · Cited by 24
Zhang, Z., Zhang, C., Miao, J., Wang, Z., Wang, Z., Cheng, Z., Wang, P., Chard, L. S., Lemoine, N. R., & Wang, Y. (2020) · Cells · doi:10.3390/cells9112438 · Cited by 24
“Systemic administration of IL-12 has been evaluated previously, but was found to produce a significant toxic effect, greatly hindering its clinical application [35].”
BackgroundJou, E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00146 · Cited by 23
Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators
Zamecnik, C. R., Lowe, M. M., Patterson, D. M., Rosenblum, M. D., & Desai, T. A. (2017) · ACS Nano · doi:10.1021/acsnano.7b06094 · Cited by 23
Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
Zhao, Q., Hu, J., Mitra, A., Cutrera, J. J., Zhang, W., Zhang, Z., Yan, J., Xia, X., Mahadeo, K. M., Livingston, J. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0631-z · Cited by 23
“, IL-12–secreting T cells) has substantial anticancer efficacy, it causes significant toxic effects in humans [18].”
BackgroundCombination therapies utilizing neoepitope-targeted vaccines
Lee, K. L., Schlom, J., & Hamilton, D. H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02729-y · Cited by 23
Sarcoma IL-12 overexpression facilitates NK cell immunomodulation
Rademacher, M. J., Cruz, A., Faber, M. L., Oldham, R. A. A., Wang, D., Medin, J. A., & Schloemer, N. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87700-2 · Cited by 23
Ding, J., Wang, T., Chen, Z., Lin, Z., Chen, X., & He, C. (2022) · Journal of Polymer Science · doi:10.1002/pol.20210955 · Cited by 23
Synthetic immunity by remote control
Gamboa, L., Zamat, A. H., & Kwong, G. A. (2020) · Theranostics · doi:10.7150/thno.41305 · Cited by 22
“For example, intratumoral injections of adenovirus carrying the genetic circuit for HSP70B-driven expression of the immunostimulatory cytokine interleukin-12 (IL-12) cause significant delay in tumor growth only in heated lesions in a murine model of melanoma [112], while systemic administration of recombinant IL-12 is…”
BackgroundLian, Q., Zheng, S., Shi, Z., Li, K., Chen, R., Wang, P., Liu, H., Chen, Y., Zhong, Q., Liu, Q., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.033 · Cited by 22
Harkos, C., Stylianopoulos, T., & Jain, R. K. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011740 · Cited by 22
Intralesional Cancer Immunotherapies
Ott, P. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.009 · Cited by 22
Koch, P. D., Rodell, C. B., Köhler, R. H., Pittet, M. J., & Weissleder, R. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2019.12.007 · Cited by 22
“Stimulating IL-12 production, predominantly produced in dendritic cells and macrophages(Lasek et al., 2014), has emerged as a therapeutic strategy for cancer immunotherapy.”
BackgroundInfluentialStay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22
“Although administration of recombinant IL-12 (rIL-12) displayed promising clinical activity in phase I trials [55], it is accompanied by an unacceptable level of adverse events (reviewed here; [56]).”
BackgroundLevitzki, A., & Klein, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816012116 · Cited by 22
“Although IL-12 was more or less abandoned as a therapeutic strategy, owing to toxicity, there has recently been a reawakening of interest, and several groups are working on targeting its delivery, to minimize toxicity (97, 98).”
BackgroundNajmuddin, S. U. F. S., Amin, Z. M., Tan, S. W., Yeap, S. K., Kalyanasundram, J., Veerakumarasivam, A., Chan, S. C., Chia, S. L., Yusoff, K., & Alitheen, N. B. (2020) · PeerJ · doi:10.7717/peerj.9761 · Cited by 22
Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer
Sun, R., Fu, J., Liang, Y., Li, L., Bai, P., Yuan, F., Gao, L., & Zhang, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3685-7 · Cited by 22
“IL-12, produced predominantly by dendritic cells, macrophages, and human B lymphoblastoid cells, possesses the ability of immune responses and anti-angiogenic activity [9, 43, 44].”
BackgroundProteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches
Dourthe, C., Julien, C., Di-Tommaso, S., Dupuy, J., Dugot‐Senant, N., Brochard, A., Bail, B. L., Blanc, J., Chiche, L., Balabaud, C. P., et al. (2021) · Hepatology · doi:10.1002/hep.31826 · Cited by 21
Next Steps for Immunotherapy in Glioblastoma
Cao, T., Wainwright, D. A., Lee-Chang, C., Miska, J. M., Sonabend, A. M., Heimberger, A. B., & Lukas, R. V. (2022) · Cancers · doi:10.3390/cancers14164023 · Cited by 22
Chen, J., Madina, B. R., Ahmadi, E., Yarovinsky, T. O., Krady, M. M., Meehan, E. V., Wang, I. C., Ye, X., Pitmon, E., Ma, X., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.034 · Cited by 21
“It is not surprising that IL-12 stand-alone therapies have so far failed to advance in the clinic despite the impressive data accumulated in mice 85 .”
BackgroundCancer Cytokines and the Relevance of 3D Cultures for Studying Those Implicated in Human Cancers
Ravi, M., Subramaniyan, A., & Balasubramanian, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25970 · Cited by 21
The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors
Bujak, J. K., Szopa, I. M., Pingwara, R., Kruczyk, O., Krzemińska, N., Mucha, J., & Majchrzak, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072292 · Cited by 21
Ultrasound and microbubble-mediated drug delivery and immunotherapy
Omata, D., Munakata, L., Maruyama, K., & Suzuki, R. (2022) · Journal of Medical Ultrasonics · doi:10.1007/s10396-022-01201-x · Cited by 21
IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing
Braun, M., Reß, M. L., Yoo, Y.-E., Scholz, C. J., Eyrich, M. K., Schlegel, P. G., & Wölfl, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1188245 · Cited by 21
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 21
Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery
Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
Nunno, V. D., Aprile, M., Gatto, L., Tosoni, A., Ranieri, L., Bartolini, S., & Franceschi, E. (2023) · Cancers · doi:10.3390/cancers15041042 · Cited by 20
Liu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 20
Martinović, K. M., Vuletić, A. M., Babović, N. L., Džodić, R. R., Konjević, G. M., & Jurišić, V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.02.024 · Cited by 20
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
Hochnadel, I., Kossatz-Boehlert, U., Jedicke, N., Lenzen, H., Manns, M. P., & Yevsa, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1359362 · Cited by 20
“Care has to be taken as unexpected side effects due to different treatment protocols may arise.(47) Overexpression of IL12 mediated by for example adenoviral delivery in in vivo HCC mouse models showed to be beneficial and prolonged survival.”
BackgroundBeyond PD-1: The Next Frontier for Immunotherapy in Melanoma
Rohatgi, A., & Kirkwood, J. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640314 · Cited by 20
“Preclinical data demonstrated the anti-tumor effects of IL-12 by multiple mechanisms and in several murine tumor models (89).”
BackgroundPreclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
Huang, J., Liu, Y., Au, B. C. Y., Barber, D. L., Arruda, A., Schambach, A., Rothe, M., Minden, M. D., Paige, C. J., & Medin, J. A. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.74 · Cited by 20
Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview
Boersma, B., Poinot, H., & Pommier, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16080974 · Cited by 19
“In addition, IL-12 induces the release of IFN γ [185] and has exhibited notable antitumor efficacy in numerous pre-clinical cancer models [186].”
BackgroundTherapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology
Lasek, W., & Zapała, Ł. (2021) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2021.0094 · Cited by 19
Self-citationPatel, E., Malkova, N. V., CROWE, D. F., Pederzoli-Ribeil, M., Fantini, D., Fanny, M., Madala, H. R., Jenkins, K. A., Yerov, O., Greene, J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0336 · Cited by 19
Tarhini, A. A., Eroglu, Z., Eljilany, I., Zager, J. S., González, R., Sarnaik, A. A., Cruse, C. W., Khushalani, N. I., Aquino, D. B. D., Abraham, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2768 · Cited by 19
The role of cytokines in shaping the future of Cancer immunotherapy
Safaei, S., Yari, A., Pourbagherian, O., & Maleki, L. A. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156888 · Cited by 19
Ahangar-Parvin, R., Mohammadi-Kordkhayli, M., Azizi, S. V., Nemati, M., Khorramdelazad, H., Taghipour, Z., Hassan, Z. M., Moazzeni, S. M., & Jafarzadeh, A. (2018) · Iranian journal of pathology · doi:10.30699/ijp.13.1.10 · Cited by 19
“IL-12 may play a major role in the development of MS and EAE by inducing differentiation of both Th1 and Th17 cells (8).”
BackgroundInfluentialOncolytic Immunotherapy: Can’t Start a Fire Without a Spark
Muscolini, M., Tassone, E., & Hiscott, J. B. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.014 · Cited by 19
Mierzejewska, J., Węgierek‐Ciura, K., Rossowska, J., Szczygieł, A., Anger, N., Szermer-Olearnik, B., Geneja, M., & Pajtasz‐Piasecka, E. (2022) · Journal of Immunology Research · doi:10.1155/2022/7508928 · Cited by 19
“Additionally, IL-12 affects tumor cells, causing increased expression of the antigen MHC I on their surface, which may facilitate tumor identification and promote the cytotoxic activity of lymphocytes [13].”
BackgroundNew Developments and Opportunities of Microbiota in Treating Breast Cancers
Meng, Z., Ye, Z., Zhu, P., Zhu, J., Fang, S., Qiu, T., Li, Y., & Meng, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.818793 · Cited by 19
“As an effective antitumor factor, IL-12 was confirmed to enhance the response to cancer immunotherapy (Lasek et al., 2014).”
BackgroundManipulation of Innate Immunity for Cancer Therapy in Dogs
Regan, D. P., & DOW, S. W. (2015) · Veterinary Sciences · doi:10.3390/vetsci2040423 · Cited by 19
“NK cells and CD4+ and CD8+ T cells [73]”
InfluentialCancer immunotherapy: Breakthrough or “deja vu, all over again”?
Sell, S. (2017) · Tumor Biology · doi:10.1177/1010428317707764 · Cited by 19
Highly Active Myeloid Therapy for Cancer
Fredrich, I. R., Halabi, E. A., Köhler, R. H., Ge, X., Garris, C., & Weissleder, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c08034 · Cited by 18
Structure and assembly of the human IL-12 signaling complex
Chen, H., Ge, X., Li, C., Zeng, J., & Wang, X. (2024) · Structure · doi:10.1016/j.str.2024.07.010 · Cited by 18
Fabian, K. P., Santiago-Sánchez, G. S., Padget, M. R., Lassoued, W., Allen, C. T., Battula, S. K., Kaufman, H. L., & Hodge, J. W. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009712 · Cited by 18
“7 But despite its potency, the development of IL- 12-based therapy has been hampered by suboptimal clinical efficacy and toxicity caused by systemic IL-12 accumulation.”
The transduction pattern of IL‐12‐encoding lentiviral vectors shapes the immunological outcome
Goyvaerts, C., Broos, K., Escors, D., Heirman, C., Raes, G., BAETSELIER, P. D., Thielemans, K., & Breckpot, K. (2015) · European Journal of Immunology · doi:10.1002/eji.201545559 · Cited by 18
Immunorelated gene polymorphisms associated with acute myeloid leukemia
Liu, Q., Hua, M., Yan, S., Zhang, C., Wang, R., Yang, X., Han, F., Hou, M., & Ma, D. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13446 · Cited by 19
An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease
Plaza, S. D., Lizak, C., Matasci, M., Mock, J., Villa, A., Neri, D., & Cazzamalli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810020 · Cited by 18
Analysis of potential biomarkers of response to IL-12 therapy
Schwarz, E. J., & Carson, W. E. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru1221-675r · Cited by 18
Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy
Ryapolova, A., Minskaia, E., Gasanov, N. B., Moroz, V., Krapivin, B., Egorov, A. D., Laktyushkin, V. S., Zhuravleva, S., Nagornych, M., Субчева, Е. Н., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010211 · Cited by 18
“…its targeted delivery by OVs can overcome this hurdle while, at the same time, taking full advantage of IL-12’s ability to activate both innate and adaptive immunity, as it induces T-helper 1 (Th1) differentiation and activates IFN-γ production in NK, CD4 + , and CD8 + T lymphocytes [10–13].”
BackgroundDiabetes-associated dysregulated cytokines and cancer
Wu, Y., Dong, Y., Liu, Y., & Vadgama, J. V. (2016) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000173 · Cited by 18
“In addition to aforementioned diabetes-associated dysregulated cytokines, other diabetes-related cytokines involved in cancer initiation and progression include C-X-C chemokine ligand 16 (CXCL16) [173- 183], IL-1 [184-187], IL-10 [188-192], IL-12 [193-195], IL-18 [196- 198], macrophage migration inhibitory factor (MIF…”
BackgroundInfluentialA tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses
Shi, W., Xu, W., Song, L., Zeng, Q., Qi, G., Qin, Y., Li, Z., Liu, X., Jiao, Z., Zhao, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.021 · Cited by 17
Ayele, K., Wakimoto, H., Nauwynck, H., Kaufman, H. L., Rabkin, S. D., & Saha, D. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.054 · Cited by 18
Núñez-Marrero, Á. R., Arroyo, N., Godoy, L. J., Rahman, M. Z., Matta, J. L., & Dutil, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27707 · Cited by 17
“IL-12 is a strong proinflammatory cytokine that induces a signaling pathway in which STAT4 and IFNG are key for anti-tumor responses [12, 34, 35].”
BackgroundKajihara, M., Takakura, K., Kanai, T., Ito, Z., Matsumoto, Y., Shimodaira, S., Okamoto, M., Ohkusa, T., & Koido, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i18.4446 · Cited by 17
Kamenšek, U., Tešić, N., Serša, G., & Čemažar, M. (2018) · Cancers · doi:10.3390/cancers10030060 · Cited by 17
“Interleukin-12 (IL-12) is a key cytokine that regulates specific immune responses against cancer cells, and, as such, it holds great potential for cancer treatment [1].”
BackgroundRevisiting the Relationship Between Alzheimer’s Disease and Cancer With a circRNA Perspective
Chen, D., Hao, S., & Xu, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647197 · Cited by 17
Hypoxia-inducible lentiviral gene expression in engineered human macrophages
Chinn, H. K., Gardell, J. L., Matsumoto, L. R., Labadie, K. P., Mihailovic, T. N., Lieberman, N. A. P., Davis, A. D., Pillarisetty, V. G., & Crane, C. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003770 · Cited by 16
“However high concentrations of proinflammatory IL-12 may result in toxic effects in off-target tissues, 13 14 therefore selective expression of transgenes is necessary.”
Qian, X., Ning, W., Yang, H. J., Chard, L. S., Pandha, H. S., Shang, G., Guo, Y., Zhang, D., Qu, Y., Wang, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62260-5 · Cited by 16
“The IL-12 can signi fi cantly enhance both innate and adaptive immune responsesinthehost,stimulatethesecretionofIFN-γ ,andremodelthe tumor microenvironment 19 .”
Kaiser, Y., Garris, C., Marinari, E., Kim, H. S., Oh, J., Pédard, M., Halabi, E. A., Choi, M., Parvanian, S., Köhler, R. H., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01533-2 · Cited by 17
Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy
Sekhon, B. K., Roubin, R. H., Li, Y., Devi, P. B., Nammi, S., Fan, K., & Sze, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146881 · Cited by 16
“Few such clinical trials administering IL-12 in cancer patients have showed encouraging results [7].”
BackgroundGehrig, S., Sami, H., & Ogris, M. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.87 · Cited by 16
Synthetic super-enhancers enable precision viral immunotherapy
Koeber, U., Matjusaitis, M., Alfazema, N., Furlong, K., Wang, Z., White, R., Hamdan, A., Dewari, P. S., Morisse, G., Navarette, M., et al. (2026) · Nature · doi:10.1038/s41586-026-10329-6 · Cited by 15
“We chose the cytokine IL-12 for evaluation as it triggers a potent inflammatory response (stimulating adaptive and innate immunity) and is effective in promoting anticancer immune responses 31,32 .”
Lipinski, B., Unmuth, L., Arras, P., Endruszeit, R., Becker, S., Rödel, J. M., Scheller, J., Pudewell, S., Floss, D. M., Krah, S., et al. (2025) · Protein Science · doi:10.1002/pro.70072 · Cited by 15
“Of note, also other next-generation engineering approaches of IL-12 have been conducted, for instance, a masking approach that relies on a tumor protease cleavable linker (Lasek et al. 2014; Mansurov et al. 2022).”
Honeder, S. E., Tomin, T., Nebel, L., Gindlhuber, J., Fritz‐Wallace, K., Schinagl, M., Heininger, C., Schittmayer, M., Ghaffari‐Tabrizi‐Wizsy, N., & Birner‐Gruenberger, R. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100095 · Cited by 15
“Interleukin-12 signaling is suggested as a promising candidate for tumor immunotherapy with potential antiangiogenic effects (44, 45).”
BackgroundLi, S., Guo, Y., Ning, W., Chen, Y., Xu, J., Zhao, C., Wang, J., Qu, Y., Zhang, M., Wang, P., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122254 · Cited by 15
Alvero, A. B., Fox, A. L., Madina, B. R., Krady, M. M., Gogoi, R. P., Chehade, H., Nakaar, V., Almassian, B., Yarovinsky, T. O., Rutherford, T., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0127 · Cited by 15
Ajaghaku, D. L., Akah, P. A., Ilodigwe, E. E., Nduka, S. O., Osonwa, U. E., & Okoye, F. B. C. (2018) · Immunological Investigations · doi:10.1080/08820139.2018.1433201 · Cited by 15
“Interleukin-12 possesses multiple biological properties that have been shown to govern immune effector actions against a variety of infections and malignancies (Lasek et al., 2014).”
BackgroundToney, N. J., Gatti-Mays, M. E., Tschernia, N. P., Strauss, J., Gulley, J. L., Schlom, J., & Donahue, R. N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109736 · Cited by 14
Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma
Eresen, A. (2024) · American Journal of Cancer Research · doi:10.62347/pmvn1173 · Cited by 14
Jiang, Z., Yang, N., Jin, J., Zhang, Z., Lu, H., Xu, L., Chen, Y., Jin, L., Zhou, L., Yang, H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011642 · Cited by 14
“By effectively reshaping the TME, SKV-012 could offer a promising avenue for cancer immunotherapy.”
Carneiro, B. A., Marron, T. U., Zamarin, D., Álvarez, E. C., Patel, S. P., Subbiah, V., Mehmi, I., El-Khoueiry, A. B., Oberoi, A., Abadier, M., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4865 · Cited by 14
Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model
Zhou, Z., Peng, F., Li, J., & Ye, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222097 · Cited by 14
YAMASHITA, M., Tasaki, M., Murakami, R., Arai, Y., Nakamura, T., & Nakao, S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.016 · Cited by 14
“IL-12 is a well-studied, strong activator of both innate and adaptive immunity through induction of interferon gamma (IFN-g).(16) The antitumor activity of an oncolytic vaccinia virus carrying human IL-7 and murine IL-12 (hIL-7/mIL-12-VV) is mostly suppressed by the depletion of CD8 T cells, indicating that subsets of…”
BackgroundAhn, H.-H., Carrington, C. A., Hu, Y., Liu, H.-W., Ng, C. C., Nam, H., PARK, A. W., Stace, C., West, W., Mao, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89124-4 · Cited by 14
Personalizing Oncolytic Virotherapy
Hamdan, F., Fusciello, M., & Cerullo, V. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.122 · Cited by 14
Cini, J. K., Dexter, S., Rezac, D. J., McAndrew, S. J., Hédou, G., Brody, R., Eraslan, R.-N., Kenney, R. T., & Mohan, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326927 · Cited by 14
Intratumoral injection of dendritic cells overexpressing interleukin‑12 inhibits melanoma growth
Yao, W., Li, Y., Zeng, L., Zhang, X., Zhou, Z., Zheng, M., & Wan, H. (2019) · Oncology Reports · doi:10.3892/or.2019.7165 · Cited by 14
Subramaniam, S., Rao, J. S. A., Ramdas, P., Ng, M. H., Kutty, M. K., Selvaduray, K. R., & Radhakrishnan, A. K. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13650 · Cited by 14
“The level of IFN- γ was significantly altered in all the groups on days 28, 35, 42 and 49 when compared against the baseline.”
BackgroundInfluentialGonzàlez-Juncà, A., Liu, F. D., Nagaraja, A. S., Mullenix, A., Lee, C.-T., Gordley, R. M., Frimannsson, D. O., Maller, O., Garrison, B. S., Iyer, D., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0030 · Cited by 14
Nanotherapeutics for immune network modulation in tumor microenvironments
Lee, J., Kim, D.-Y., Le, Q., & Oh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.005 · Cited by 14
Han, M., Nguyen, B., Lee, J. Y., Browning, E., Zhang, J., Mukhopadhyay, A., Gujar, R., Salazar, J. V., Hermiz, R., Svenson, L., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0834 · Cited by 14
Piao, H., Jiang, Y., Jin, S., Shi, J., Yu, J. G., Wang, W., Du, Z., Yao, H., Liu, Q., Li, N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1614640 · Cited by 13
In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation
Shi, Y., Hou, Y., Mabrouk, M. T., Yu, C., & Yang, Y. (2025) · Advanced Science · doi:10.1002/advs.202509836 · Cited by 14
Exosomes: Recent Advances and Challenges as Targeted Therapeutic Delivery Vesicles
Jadhav, S., Kumar, A., & Gulbake, A. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022044495 · Cited by 13
Revitalizing Cytokine‐Based Cancer Immunotherapy through Advanced Delivery Systems
Chen, P., Paraiso, W. K. D., & Cabral, H. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300275 · Cited by 13
Gene Immunotherapy of Colon Carcinoma with IL-2 and IL-12 Using Gene Electrotransfer
Komel, T., Omerzel, M., Kamenšek, U., Žnidar, K., Tratar, U. L., Kranjc, S., Dolinar, K., Pirkmajer, S., Serša, G., & Čemažar, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612900 · Cited by 13
“Several studies suggest that pro-inflammatory interleukins such as IL-2 and IL-12 play an important role in the activation and targeting of cytotoxic T lymphocytes and other immune cells to the tumour microenvironment [32,33].”
BackgroundEnhanced CXCR4 Expression of Human CD8Low T Lymphocytes Is Driven by S1P4
Burkard, T., Dreis, C., Juan, M. H. S., Huhn, M., Weigert, A., Pfeilschifter, J. M., & Radeke, H. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668884 · Cited by 13
“Dendritic cells are themainproducers of IL12, a modulator of the immune response of CD8 T lymphocytes (53).”
BackgroundMartinović, K. M., Babović, N. L., Džodić, R. R., Jurišić, V., Ninković, A. Z., & Konjević, G. M. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000289 · Cited by 13
Advances in engineering and delivery strategies for cytokine immunotherapy
Bohmer, M., Xue, Y., Jankovic, K. E., & Dong, Y. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2208344 · Cited by 12
“However, IL-12 is highly toxic when administered intravenously, as exemplified by a phase II trial wherein 2 of 17 patients died from toxicity [78].”
BackgroundSynthetic Cells and Molecules in Cellular Immunotherapy
Lin, H., Li, C., Zhang, W., Wu, B., Wang, Y., Wang, S., Wang, D., Li, X., & Huang, H. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.94346 · Cited by 12
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
Wang, G., Liu, Y., Liu, S., Lin, Y., & Hu, C. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012647 · Cited by 12
Kamenšek, U., Tešić, N., Serša, G., Kos, Š., & Čemažar, M. (2016) · Plasmid · doi:10.1016/j.plasmid.2016.11.004 · Cited by 12
Jarosz–Biej, M., Smolarczyk, R., Cichoń, T., Kułach, N., Czapla, J., Matuszczak, S., & Szala, S. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0337-y · Cited by 12
“Th0 cells into Th1 phenotype, enhances antibody-dependent cell cytotoxicity against cancer cells, and induces IgG antibodies and inhibits the synthesis of IgE antibodies by B lymphocytes (Lasek et al. 2014).”
BackgroundInfluentialBiological Response Modifier in Cancer Immunotherapy
Liu, R., Luo, F., Liu, X., Wang, L., Yang, J., Deng, Y., Huang, E., Qian, J., Lu, Z., Jiang, X., et al. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_2 · Cited by 12
“For instance, resiquimod, a TLR7/8 agonist, has shown potential value because of its capability to enhance the level of IL-12 and TNF-α and inhibit regulatory T cells (Treg) function (Prins et al. 2006).”
BackgroundInfluentialSymptomatic subependymomas of the ventricles. Review of twenty consecutive cases.
Vitanovics, D., Afra, D., Nagy, G., Hanzély, Z., Turányi, E., & Banczerowski, P. (2014) · PubMed · Cited by 12
Collagen-binding IL-12 inflames ‘cold’ tumours
Scheller, J., & Lang, P. A. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0560-7 · Cited by 12
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.